Options Update: Cardiome Pharma (CRME) & EnCana (ECA)
Cardiome Pharma (CRME)
CRME February volatility above 200 into FDA ruling.
CRME is recently trading at $6.53.
The FDA's cardiovascular and renal drugs advisory committee voted in favor of CRME's Vernakalant, a drug to restore normal heart rhythm in patients with arterial fibrillation. The FDA is expected to make a decision on whether to approve Vernakalant soon.
CRME February option implied volatility of 202 is above 6-month average option implied volatility is 131, suggesting larger risk.
EnCana (ECA)
ECA volatility is flat as oil trades $91.30 into OPEC meeting.
ECA is a leading North American natural gas producer with a market cap of $47 billion.
WTI Crude Oil futures are up .34% to $91.30.
ECA overall option implied volatility of 33 is near its 6-month average of 31, suggesting non-directional price fluctuations.
"
About Paul Foster
Paul Foster is a former member of the Chicago Board Options Exchange with 21-years of professional experience in the capital markets, investments, trading, corporate finance, arbitrage, options and mergers & acquisitions. His writing about the options market has appeared in a wide variety of publications.
View Paul Foster's post archive >
